High Response Rates With Larotrectinib in Tumor Types With TRK Fusions
Related Biotechnology, Pharmaceutical and Healthcare News
Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
Original Article: High Response Rates With Larotrectinib in Tumor Types With TRK Fusions
NEXT ARTICLE
More From BioPortfolio on "High Response Rates With Larotrectinib in Tumor Types With TRK Fusions"
